IT201700041723A1 - Nuovi inibitori selettivi di HDAC6 - Google Patents

Nuovi inibitori selettivi di HDAC6

Info

Publication number
IT201700041723A1
IT201700041723A1 IT102017000041723A IT201700041723A IT201700041723A1 IT 201700041723 A1 IT201700041723 A1 IT 201700041723A1 IT 102017000041723 A IT102017000041723 A IT 102017000041723A IT 201700041723 A IT201700041723 A IT 201700041723A IT 201700041723 A1 IT201700041723 A1 IT 201700041723A1
Authority
IT
Italy
Prior art keywords
new
selective inhibitors
hdac6 selective
hdac6
inhibitors
Prior art date
Application number
IT102017000041723A
Other languages
English (en)
Italian (it)
Inventor
Barbara Vergani
Gianluca Caprini
Gianluca Fossati
Maria Lattanzio
Mattia Marchini
Gianfranco Pavich
Marcello Pezzuto
Chiara Ripamonti
Giovanni Sandrone
Christian Steinkuhler
Andrea Stevenazzi
Original Assignee
Italfarmaco Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Italfarmaco Spa filed Critical Italfarmaco Spa
Priority to IT102017000041723A priority Critical patent/IT201700041723A1/it
Priority to TW107112124A priority patent/TWI813564B/zh
Priority to RU2019132212A priority patent/RU2764718C2/ru
Priority to HRP20230789TT priority patent/HRP20230789T8/hr
Priority to ES18716299T priority patent/ES2951476T3/es
Priority to LTEPPCT/EP2018/059468T priority patent/LT3562810T/lt
Priority to SI201830949T priority patent/SI3562810T1/sl
Priority to PL18716299.5T priority patent/PL3562810T3/pl
Priority to EP18716299.5A priority patent/EP3562810B1/en
Priority to KR1020197033482A priority patent/KR102525375B1/ko
Priority to RS20230576A priority patent/RS64376B1/sr
Priority to CN201880024895.9A priority patent/CN110546140B/zh
Priority to HUE18716299A priority patent/HUE063079T2/hu
Priority to CA3056381A priority patent/CA3056381A1/en
Priority to JP2019556238A priority patent/JP7241025B2/ja
Priority to SM20230228T priority patent/SMT202300228T1/it
Priority to DK18716299.5T priority patent/DK3562810T3/da
Priority to PE2019001995A priority patent/PE20200446A1/es
Priority to FIEP18716299.5T priority patent/FI3562810T3/fi
Priority to PCT/EP2018/059468 priority patent/WO2018189340A1/en
Priority to MX2019011876A priority patent/MX2019011876A/es
Priority to PT187162995T priority patent/PT3562810T/pt
Priority to AU2018252172A priority patent/AU2018252172B9/en
Priority to US16/491,827 priority patent/US11351178B2/en
Priority to BR112019021078-4A priority patent/BR112019021078B1/pt
Priority to NZ756603A priority patent/NZ756603A/en
Priority to ARP180100940A priority patent/AR111466A1/es
Publication of IT201700041723A1 publication Critical patent/IT201700041723A1/it
Priority to IL268955A priority patent/IL268955B/en
Priority to CL2019002869A priority patent/CL2019002869A1/es
Priority to CONC2019/0011993A priority patent/CO2019011993A2/es
Priority to JP2022164773A priority patent/JP2022191395A/ja
Priority to CY20231100364T priority patent/CY1126110T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
IT102017000041723A 2017-04-14 2017-04-14 Nuovi inibitori selettivi di HDAC6 IT201700041723A1 (it)

Priority Applications (32)

Application Number Priority Date Filing Date Title
IT102017000041723A IT201700041723A1 (it) 2017-04-14 2017-04-14 Nuovi inibitori selettivi di HDAC6
TW107112124A TWI813564B (zh) 2017-04-14 2018-04-09 新穎選擇性hdac6抑制劑
SM20230228T SMT202300228T1 (it) 2017-04-14 2018-04-12 Derivati dell’acido benzoidrossamico come inibitori selettivi di hdac6
DK18716299.5T DK3562810T3 (da) 2017-04-14 2018-04-12 Benzhydroxamsyre-derivater som selektive hdac6-inhibitorer
ES18716299T ES2951476T3 (es) 2017-04-14 2018-04-12 Derivados del ácido benzhidroxámico como inhibidores selectivos de HDAC6
LTEPPCT/EP2018/059468T LT3562810T (lt) 2017-04-14 2018-04-12 Benzhidroksamo rūgšties dariniai kaip selektyvūs hdac6 inhibitoriai
SI201830949T SI3562810T1 (sl) 2017-04-14 2018-04-12 Derivati benzhidroksamske kisline kot selektivni zaviralci HDAC6
PL18716299.5T PL3562810T3 (pl) 2017-04-14 2018-04-12 Pochodne kwasu benzhydroksaminowego jako selektywne inhibitory hdac6
EP18716299.5A EP3562810B1 (en) 2017-04-14 2018-04-12 Benzhydroxamic acid derivatives as selective hdac6 inhibitors
KR1020197033482A KR102525375B1 (ko) 2017-04-14 2018-04-12 선택적 hdac6 저해제
RS20230576A RS64376B1 (sr) 2017-04-14 2018-04-12 Derivati benzhidroksaminske kiseline kao selektivni inhibitori hdac6
CN201880024895.9A CN110546140B (zh) 2017-04-14 2018-04-12 选择性hdac6抑制剂
HUE18716299A HUE063079T2 (hu) 2017-04-14 2018-04-12 Benzhidroxámsav-származékok mint szelektív HDAC6 inhibitorok
CA3056381A CA3056381A1 (en) 2017-04-14 2018-04-12 Substituted benzamide derivatives and pharmaceutical compositions thereof useful as hdac6 inhibitors
JP2019556238A JP7241025B2 (ja) 2017-04-14 2018-04-12 選択的hdac6阻害剤
RU2019132212A RU2764718C2 (ru) 2017-04-14 2018-04-12 Селективные ингибиторы hdac6
PE2019001995A PE20200446A1 (es) 2017-04-14 2018-04-12 Nuevos inhibidores de hdac6 selectivos
MX2019011876A MX2019011876A (es) 2017-04-14 2018-04-12 Nuevos inhibidores de hdac6 selectivos.
HRP20230789TT HRP20230789T8 (hr) 2017-04-14 2018-04-12 Derivati benzhidroksamske kiseline kao selektivni inhibitori hdac6
PCT/EP2018/059468 WO2018189340A1 (en) 2017-04-14 2018-04-12 Selective hdac6 inhibitors
FIEP18716299.5T FI3562810T3 (fi) 2017-04-14 2018-04-12 Bentshydroksaamihapon johdannaisia selektiivisinä hdac6:n estäjinä
PT187162995T PT3562810T (pt) 2017-04-14 2018-04-12 Derivados de ácido benzidroxâmico como inibidores seletivos de hdac6
AU2018252172A AU2018252172B9 (en) 2017-04-14 2018-04-12 Selective HDAC6 inhibitors
US16/491,827 US11351178B2 (en) 2017-04-14 2018-04-12 Selective HDAC6 inhibitors
BR112019021078-4A BR112019021078B1 (pt) 2017-04-14 2018-04-12 Composto da fórmula (i) e (ii) e sais isômeros e pró-fármacos farmaceuticamente aceitáveis do mesmo, composto para uso e composição farmacêutica
NZ756603A NZ756603A (en) 2017-04-14 2018-04-12 Selective hdac6 inhibitors
ARP180100940A AR111466A1 (es) 2017-04-14 2018-04-13 Inhibidores de hdac6 selectivos
IL268955A IL268955B (en) 2017-04-14 2019-08-27 Selective hdac6 inhibitors
CL2019002869A CL2019002869A1 (es) 2017-04-14 2019-10-08 Inhibidores selectivos hdac6.
CONC2019/0011993A CO2019011993A2 (es) 2017-04-14 2019-10-28 Inhibidores selectivos de hdac6
JP2022164773A JP2022191395A (ja) 2017-04-14 2022-10-13 選択的hdac6阻害剤
CY20231100364T CY1126110T1 (el) 2017-04-14 2023-07-26 Παραγωγα βενζοϋδροξαμικου οξεος ως εκλεκτικοι αναστολε1σ του hdac6

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102017000041723A IT201700041723A1 (it) 2017-04-14 2017-04-14 Nuovi inibitori selettivi di HDAC6

Publications (1)

Publication Number Publication Date
IT201700041723A1 true IT201700041723A1 (it) 2018-10-14

Family

ID=59700099

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102017000041723A IT201700041723A1 (it) 2017-04-14 2017-04-14 Nuovi inibitori selettivi di HDAC6

Country Status (30)

Country Link
US (1) US11351178B2 (cg-RX-API-DMAC10.html)
EP (1) EP3562810B1 (cg-RX-API-DMAC10.html)
JP (2) JP7241025B2 (cg-RX-API-DMAC10.html)
KR (1) KR102525375B1 (cg-RX-API-DMAC10.html)
CN (1) CN110546140B (cg-RX-API-DMAC10.html)
AR (1) AR111466A1 (cg-RX-API-DMAC10.html)
AU (1) AU2018252172B9 (cg-RX-API-DMAC10.html)
CA (1) CA3056381A1 (cg-RX-API-DMAC10.html)
CL (1) CL2019002869A1 (cg-RX-API-DMAC10.html)
CO (1) CO2019011993A2 (cg-RX-API-DMAC10.html)
CY (1) CY1126110T1 (cg-RX-API-DMAC10.html)
DK (1) DK3562810T3 (cg-RX-API-DMAC10.html)
ES (1) ES2951476T3 (cg-RX-API-DMAC10.html)
FI (1) FI3562810T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20230789T8 (cg-RX-API-DMAC10.html)
HU (1) HUE063079T2 (cg-RX-API-DMAC10.html)
IL (1) IL268955B (cg-RX-API-DMAC10.html)
IT (1) IT201700041723A1 (cg-RX-API-DMAC10.html)
LT (1) LT3562810T (cg-RX-API-DMAC10.html)
MX (1) MX2019011876A (cg-RX-API-DMAC10.html)
NZ (1) NZ756603A (cg-RX-API-DMAC10.html)
PE (1) PE20200446A1 (cg-RX-API-DMAC10.html)
PL (1) PL3562810T3 (cg-RX-API-DMAC10.html)
PT (1) PT3562810T (cg-RX-API-DMAC10.html)
RS (1) RS64376B1 (cg-RX-API-DMAC10.html)
RU (1) RU2764718C2 (cg-RX-API-DMAC10.html)
SI (1) SI3562810T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202300228T1 (cg-RX-API-DMAC10.html)
TW (1) TWI813564B (cg-RX-API-DMAC10.html)
WO (1) WO2018189340A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115737549A (zh) * 2022-11-24 2023-03-07 北京鑫开元医药科技有限公司 一种具有hdac抑制活性的注射液及其制备方法和用途

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
CN109942564A (zh) * 2019-04-16 2019-06-28 四川大学华西医院 一种组蛋白去乙酰化酶抑制剂及其制备方法和用途
CN115443329A (zh) 2019-06-27 2022-12-06 乔治华盛顿大学国会特许非营利公司 Hdac6激活的巨噬细胞、其组合物及用途
WO2021013163A1 (en) * 2019-07-23 2021-01-28 Taipei Medical University Histone deacetylase 6 inhibitors and method for treating neuropathic pain
CN114727974A (zh) 2019-07-30 2022-07-08 艾科尼佐治疗股份有限公司 Hdac6抑制剂及其用途
KR20220119653A (ko) * 2019-12-20 2022-08-30 테나야 테라퓨틱스, 인코포레이티드 플루오로알킬-옥사디아졸 및 이의 용도
CA3189738A1 (en) * 2020-08-07 2022-02-10 Italfarmaco S.P.A. Novel oxadiazole-based selective hdac6 inhibitors
CN112250638B (zh) * 2020-11-13 2022-05-03 郑州大学 一种1,3-二芳基-1,2,4-三氮唑类化合物及其制备方法和应用
WO2022169985A1 (en) 2021-02-03 2022-08-11 Eikonizo Therapeutics, Inc. Hdac6 inhibitors and uses thereof
IT202100009926A1 (it) * 2021-04-20 2022-10-20 Italfarmaco Spa Una combinazione comprendente un inibitore di hdac6 specifico e almeno un inibitore del checkpoint ctla4
TW202340480A (zh) 2021-11-23 2023-10-16 義大利商義大利藥品股份有限公司 檢測rna生物標記之方法
AU2023250964A1 (en) 2022-04-08 2024-11-07 Eikonizo Therapeutics, Inc. Oxadiazole hdac6 inhibitors and uses thereof
WO2023219456A1 (ko) * 2022-05-12 2023-11-16 숙명여자대학교 산학협력단 퀴놀린 계열 히스톤디아세틸화 효소 저해활성물질, 이의 제조방법 및 이를 유효성분으로 포함하는 약학적 조성물
KR20240043709A (ko) * 2022-09-27 2024-04-03 사회복지법인 삼성생명공익재단 히스톤 탈아세틸화효소 억제제를 포함하는 암 치료용 조성물, 및 암 면역치료용 항암 보조제
CN115611823B (zh) * 2022-10-27 2024-09-27 新天地医药技术研究院(郑州)有限公司 一种1,2,4-三氮唑-苯基异羟肟酸类化合物、制备方法和应用
AU2024206778A1 (en) * 2023-01-06 2025-07-24 Sparrow Pharmaceuticals, Inc. Methods and compositions for treating hsd-1-mediated disorders
CN121108070A (zh) * 2025-09-22 2025-12-12 徐州医科大学 双苯基噁二唑类化合物或其盐、其制备方法及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011021209A1 (en) * 2009-07-07 2011-02-24 Portsmouth Technologies Llc Histone deacetylase inhibitors
WO2012106343A2 (en) * 2011-02-01 2012-08-09 The Board Of Trustees Of The University Of Illinois Hdac inhibitors and therapeutic methods using the same
WO2012178208A2 (en) * 2011-06-24 2012-12-27 The Trustees Of The Stevens Institute Of Technology Selective inhibitors of histone deacetylase isoform 6 and methods thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04007191A (es) 2002-01-23 2005-03-31 Bayer Pharmaceuticals Corp Derivados de pirimidina como inhibidores de rho-quinasa.
JP2008504345A (ja) 2004-07-02 2008-02-14 ノボ ノルディスク アクティーゼルスカブ コンデンスチオフェン誘導体(condensedthiophenederivatives)およびそれらのサイクリックGLP−1アゴニストとしての使用
GB0607899D0 (en) 2006-04-03 2006-05-31 Glaxo Group Ltd Process for preparing heterocyclic derivatives
WO2009002534A1 (en) 2007-06-26 2008-12-31 Gilead Colorado, Inc. Imidazopyridinyl thiazolyl histone deacetylase inhibitors
CA2765678A1 (en) 2009-06-22 2010-12-29 Christopher Blackburn Substituted hydroxamic acids and uses thereof
JP5518397B2 (ja) 2009-08-12 2014-06-11 富士フイルム株式会社 水性インク組成物、複合粒子の製造方法、インクセット、及び、画像形成方法
WO2011106650A2 (en) 2010-02-27 2011-09-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease
NZ610225A (en) * 2010-11-16 2015-08-28 Acetylon Pharmaceuticals Inc Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
HRP20181965T1 (hr) 2013-12-12 2019-02-08 Chong Kun Dang Pharmaceutical Corp. Novi derivati azaindola kao selektivni inhibitori histonske deacetilaze (hdac) i farmaceutski pripravci koji ih sadrže
KR101685639B1 (ko) 2014-01-03 2016-12-12 주식회사 종근당 신규한 인돌 유도체 화합물 및 이를 포함하는 약제학적 조성물
TW201625620A (zh) * 2014-05-14 2016-07-16 美國科羅拉多州立大學 作為蛋白去乙醯酶抑制劑及雙蛋白去乙醯酶蛋白激酶抑制劑之雜環氧肟酸及其使用方法
MX388409B (es) * 2014-06-12 2025-03-19 Cedars Sinai Medical Center Composiciones y metodos para tratar canceres.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011021209A1 (en) * 2009-07-07 2011-02-24 Portsmouth Technologies Llc Histone deacetylase inhibitors
WO2012106343A2 (en) * 2011-02-01 2012-08-09 The Board Of Trustees Of The University Of Illinois Hdac inhibitors and therapeutic methods using the same
WO2012178208A2 (en) * 2011-06-24 2012-12-27 The Trustees Of The Stevens Institute Of Technology Selective inhibitors of histone deacetylase isoform 6 and methods thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HARISH RAJAK ET AL: "2,5-Disubstituted-1,3,4-oxadiazoles/thiadiazole as surface recognition moiety: Design and synthesis of novel hydroxamic acid based histone deacetylase inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 21, no. 19, 3 August 2011 (2011-08-03), pages 5735 - 5738, XP028286354, ISSN: 0960-894X, [retrieved on 20110808], DOI: 10.1016/J.BMCL.2011.08.022 *
SERGIO VALENTE ET AL: "1,3,4-Oxadiazole-Containing Histone Deacetylase Inhibitors: Anticancer Activities in Cancer Cells", JOURNAL OF MEDICINAL CHEMISTRY, vol. 57, no. 14, 24 July 2014 (2014-07-24), pages 6259 - 6265, XP055416600, ISSN: 0022-2623, DOI: 10.1021/jm500303u *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115737549A (zh) * 2022-11-24 2023-03-07 北京鑫开元医药科技有限公司 一种具有hdac抑制活性的注射液及其制备方法和用途

Also Published As

Publication number Publication date
CY1126110T1 (el) 2023-11-15
HUE063079T2 (hu) 2023-12-28
TWI813564B (zh) 2023-09-01
SMT202300228T1 (it) 2023-09-06
HRP20230789T1 (hr) 2023-10-27
US20210128577A1 (en) 2021-05-06
RU2019132212A3 (cg-RX-API-DMAC10.html) 2021-05-14
US11351178B2 (en) 2022-06-07
CO2019011993A2 (es) 2020-01-17
ES2951476T3 (es) 2023-10-23
PE20200446A1 (es) 2020-02-28
CN110546140A (zh) 2019-12-06
AR111466A1 (es) 2019-07-17
FI3562810T3 (fi) 2023-07-27
RU2764718C2 (ru) 2022-01-19
AU2018252172B2 (en) 2021-11-04
BR112019021078A2 (pt) 2020-05-12
MX2019011876A (es) 2020-01-09
SI3562810T1 (sl) 2023-09-29
HRP20230789T8 (hr) 2024-01-05
KR102525375B1 (ko) 2023-04-27
NZ756603A (en) 2021-12-24
PT3562810T (pt) 2023-07-31
CA3056381A1 (en) 2018-10-18
LT3562810T (lt) 2023-08-10
DK3562810T3 (da) 2023-07-24
KR20190141180A (ko) 2019-12-23
AU2018252172A1 (en) 2019-10-17
JP2022191395A (ja) 2022-12-27
EP3562810A1 (en) 2019-11-06
WO2018189340A1 (en) 2018-10-18
RS64376B1 (sr) 2023-08-31
CN110546140B (zh) 2023-05-16
JP7241025B2 (ja) 2023-03-16
IL268955A (en) 2019-10-31
AU2018252172B9 (en) 2021-12-02
TW201902476A (zh) 2019-01-16
JP2020516671A (ja) 2020-06-11
IL268955B (en) 2022-01-01
CL2019002869A1 (es) 2020-04-24
PL3562810T3 (pl) 2023-09-18
RU2019132212A (ru) 2021-05-14
EP3562810B1 (en) 2023-05-03

Similar Documents

Publication Publication Date Title
IL269196A (en) Novel inhibitors
IL283639A (en) Kif18a inhibitors
IL268955B (en) Selective hdac6 inhibitors
IL263586A (en) Inhibitors of the menin-mll interaction
DK3612525T3 (da) Pd-1-/pd-l1-inhibitorer
EP3541932A4 (en) INHIBITORS OF CRISPR-CAS9
DK3571192T3 (da) Jak1-selektive inhibitorer
IL280863A (en) Autotaxin inhibitors and uses thereof
LT3303334T (lt) Tirozinkinazės inhibitoriai
DK3672976T3 (da) Bcl-2-hæmmere
DK3442972T3 (da) Bromdomænehæmmere
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
DK3433368T3 (da) Transreplikerende rna
DK3984996T3 (da) Aminopyridin-SSAO-inhibitorer
IL294381A (en) Pcna inhibitors
MA44474A (fr) Nouveaux inhibiteurs de la ferroportine
DK3681884T3 (da) Rad51-inhibitorer
IL269602B (en) Cryopreservation method
EP3313828A4 (en) METALLO-BETA-Lactamase INHIBITORS
DK3341379T3 (da) EZH2-hæmmere
DK3630744T3 (da) Pyrazol-magl-inhibitorer
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
DK3795167T3 (da) Pd-1-peptidinhibitorer
EP3600301A4 (en) KDM4 INHIBITORS
ES2927352T8 (es) Inhibidores selectivos de HDAC6, método de preparación de los mismos y aplicación de los mismos